Dr. Sid Kerkar talks to OncologyTube about EXUMA’s rPOC SC and in vivo GCAR programs
From OncologyTube: “EXUMA Biotech’s VP of Oncology R&D, Dr. Sid Kerkar, Reveals Preclinical Data From Its Subcutaneous CAR-TaNK And In Vivo CAR Cell And Gene Therapy Programs” EXUMA Biotech’s Subcutaneous CAR-TaNK and In Vivo CAR Cell And Gene Therapy Programs @EXUMABiotech #celltherapy #genetherapy #biotech
Dr. Sid Kerkar talks to VJHemOnc at AACR 2022 about rPOC SC
From VJHemOnc: “Sid P. Kerkar, MD, Exuma Biotech, West Palm Beach, FL, gives an overview of a novel subcutaneous chimeric antigen receptor T-cell (CAR-T) therapy consisting of both T-cell and natural killer (NK) features. Dr Kerkar briefly summarizes the underlying biology of this novel CAR-T treatment, as well as the short manufacturing period required for […]
Generation of tertiary lymphoid structures and CD3pos CD8pos CD56pos NKG2Dpos CAR TaNK cells following subcutaneous injection of CD3-directed lentiviral vector-loaded PBMC
Abstract #560 Key Messages: Subcutaneous (SC) injection of peripheral blood mononuclear cells (PBMC) loaded for 4hrs with CD3-directed lentivector (LV) generate a novel CAR T and NK-like (TaNK) cell capable of enhanced proliferation and target elimination Following SC administration, CAR expression and expansion initiates at the site of injection from tertiary lymphoid structures comprised of […]
In vivo delivery of a novel CD3-targeted Lentiviral Vector generates CD19 CAR-T cells in two different humanized mouse models and results in complete B cell depletion
Abstract #3294 Key Messages: In vivo CD3-targeted Lentivectors (LV) delivery of CAR-T transgenes represents a promising CAR-T gene therapy approach (GCAR) CD3-directed CAR LV generate CD19 CAR-T cells in vivo, resulting in a complete depletion of hCD20+ B cells in circulation and in lymphoid organs This novel approach for the rapid and direct formation of […]
EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting
West Palm Beach, Florida- March 15, 2022- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at […]
EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies
West Palm Beach, Fl., – December 21st, 2021- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 […]
EXUMA Biotech to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
WEST PALM BEACH, FL., September 22, 2021- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced that Chairman and Chief Executive Officer, Gregory Frost, Ph.D., will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, […]
Building Scientific Trust Virtually
“How do you build, manage, and grow global oncology teams in opposite time zones amidst a pandemic? It’s a question I asked myself as I accepted a new position eight months into the COVID-19 lockdown, knowing that my first interactions with a large part of our global teams would not be in person and that […]
Subcutaneous injection of total nucleated cells rapidly isolated following four-hour peripheral whole blood exposure to CD3-directed CAR-T lentiviruses with a synthetic driver results in robust CAR-T proliferation and anti-tumor immunity
Abstract #1511 Key Messages Here we describe a novel approach for the rapid isolation of total nucleated cells (TNC) reverse eluted off a leukocyte reduction filter from whole blood exposed for four hours to CD3-directed CAR-T Lentiviruses (LV) CD3-directed CAR-T LVs induce TCR internalization (CD3 Dimming) in T cells including Naïve and Naïve-derived T cells […]
EXUMA Biotech on NPR’s TechNation with Dr. Moira Gunn
“On this week’s Tech Nation, Moira speaks with Dr. Greg Frost, the CEO of Exuma Biotech. He explains how gene therapy for cancer is currently a 6 to 8 week proposition, and requires the patient to undergo chemotherapy. Exuma’s aim is to reduce the time to 4 hours and eliminate the chemotherapy”
